These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
379 related articles for article (PubMed ID: 30628663)
1. miR‑505 inhibits cell growth and EMT by targeting MAP3K3 through the AKT‑NFκB pathway in NSCLC cells. Tang H; Lv W; Sun W; Bi Q; Hao Y Int J Mol Med; 2019 Mar; 43(3):1203-1216. PubMed ID: 30628663 [TBL] [Abstract][Full Text] [Related]
2. miR‑379 inhibits cell proliferation and epithelial‑mesenchymal transition by targeting CHUK through the NF‑κB pathway in non‑small cell lung cancer. Liu B; Wang Z; Cheng S; Du L; Yin Y; Yang Z; Zhou J Mol Med Rep; 2019 Aug; 20(2):1418-1428. PubMed ID: 31173238 [TBL] [Abstract][Full Text] [Related]
3. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis. Lu C; Shan Z; Hong J; Yang L Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966 [TBL] [Abstract][Full Text] [Related]
4. Tumor-suppressive effects of microRNA-181d-5p on non-small-cell lung cancer through the CDKN3-mediated Akt signaling pathway in vivo and in vitro. Gao LM; Zheng Y; Wang P; Zheng L; Zhang WL; Di Y; Chen LL; Yin XB; Tian Q; Shi SS; Xu SF Am J Physiol Lung Cell Mol Physiol; 2019 May; 316(5):L918-L933. PubMed ID: 30628487 [TBL] [Abstract][Full Text] [Related]
5. MiroRNA-188 Acts as Tumor Suppressor in Non-Small-Cell Lung Cancer by Targeting MAP3K3. Zhao L; Ni X; Zhao L; Zhang Y; Jin D; Yin W; Wang D; Zhang W Mol Pharm; 2018 Apr; 15(4):1682-1689. PubMed ID: 29528232 [TBL] [Abstract][Full Text] [Related]
6. MiR-182 inhibits the epithelial to mesenchymal transition and metastasis of lung cancer cells by targeting the Met gene. Li Y; Zhang H; Li Y; Zhao C; Fan Y; Liu J; Li X; Liu H; Chen J Mol Carcinog; 2018 Jan; 57(1):125-136. PubMed ID: 28940757 [TBL] [Abstract][Full Text] [Related]
7. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling. Tang Y; Xiao G; Chen Y; Deng Y Anticancer Drugs; 2018 Sep; 29(8):725-735. PubMed ID: 29916897 [TBL] [Abstract][Full Text] [Related]
8. Sirtuin 7 promotes non‑small cell lung cancer progression by facilitating G1/S phase and epithelial‑mesenchymal transition and activating AKT and ERK1/2 signaling. Zhao Y; Ye X; Chen R; Gao Q; Zhao D; Ling C; Qian Y; Xu C; Tao M; Xie Y Oncol Rep; 2020 Sep; 44(3):959-972. PubMed ID: 32705247 [TBL] [Abstract][Full Text] [Related]
9. miR-99a suppresses the metastasis of human non-small cell lung cancer cells by targeting AKT1 signaling pathway. Yu SH; Zhang CL; Dong FS; Zhang YM J Cell Biochem; 2015 Feb; 116(2):268-76. PubMed ID: 25187230 [TBL] [Abstract][Full Text] [Related]
10. MiR-770 inhibits tumorigenesis and EMT by targeting JMJD6 and regulating WNT/β-catenin pathway in non-small cell lung cancer. Zhang Z; Yang Y; Zhang X Life Sci; 2017 Nov; 188():163-171. PubMed ID: 28882645 [TBL] [Abstract][Full Text] [Related]
11. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer. Zhou Y; Li S; Li J; Wang D; Li Q Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819 [TBL] [Abstract][Full Text] [Related]
12. miR‑593 inhibits proliferation and invasion and promotes apoptosis in non‑small cell lung cancer cells by targeting SLUG‑associated signaling pathways. Wei F; Wang M; Li Z; Wang Y; Zhou Y Mol Med Rep; 2019 Dec; 20(6):5172-5182. PubMed ID: 31661137 [TBL] [Abstract][Full Text] [Related]
13. Inactivation of M2 AChR/NF-κB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC). Zhao Q; Yue J; Zhang C; Gu X; Chen H; Xu L Oncotarget; 2015 Oct; 6(30):29335-46. PubMed ID: 26336823 [TBL] [Abstract][Full Text] [Related]
14. MAP3K3 expression in tumor cells and tumor-infiltrating lymphocytes is correlated with favorable patient survival in lung cancer. He Y; Wang L; Liu W; Zhong J; Bai S; Wang Z; Thomas DG; Lin J; Reddy RM; Ramnath N; Carrott PW; Lynch WR; Orringer MB; Chang AC; Beer DG; Chen G Sci Rep; 2015 Jun; 5():11471. PubMed ID: 26088427 [TBL] [Abstract][Full Text] [Related]
15. MiR-138 inhibits cell proliferation and reverses epithelial-mesenchymal transition in non-small cell lung cancer cells by targeting GIT1 and SEMA4C. Li J; Wang Q; Wen R; Liang J; Zhong X; Yang W; Su D; Tang J J Cell Mol Med; 2015 Dec; 19(12):2793-805. PubMed ID: 26283050 [TBL] [Abstract][Full Text] [Related]
16. MicroRNA-422a functions as a tumor suppressor in non-small cell lung cancer through SULF2-mediated TGF-β/SMAD signaling pathway. Li WQ; Zhang JP; Wang YY; Li XZ; Sun L Cell Cycle; 2019 Aug; 18(15):1727-1744. PubMed ID: 31204561 [TBL] [Abstract][Full Text] [Related]
17. B-Myb Mediates Proliferation and Migration of Non-Small-Cell Lung Cancer via Suppressing IGFBP3. Fan X; Wang Y; Jiang T; Cai W; Jin Y; Niu Y; Zhu H; Bu Y Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772705 [TBL] [Abstract][Full Text] [Related]
18. MicroRNA‑103 modulates tumor progression by targeting KLF7 in non‑small cell lung cancer. Li K; Yuan C Int J Mol Med; 2020 Sep; 46(3):1013-1028. PubMed ID: 32582959 [TBL] [Abstract][Full Text] [Related]
19. Knockdown of LncRNA-XIST Suppresses Proliferation and TGF-β1-Induced EMT in NSCLC Through the Notch-1 Pathway by Regulation of miR-137. Wang X; Zhang G; Cheng Z; Dai L; Jia L; Jing X; Wang H; Zhang R; Liu M; Jiang T; Yang Y; Yang M Genet Test Mol Biomarkers; 2018 Jun; 22(6):333-342. PubMed ID: 29812958 [TBL] [Abstract][Full Text] [Related]
20. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway. Gao BB; Wang SX Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]